Page 142 - CW E-Magazine (2-1-2024)

Top Stories Pharmaceuticals

OUTLOOK DISTRIBUTION DEAL
Energy storage to attract highest investment among Biocon Biologics partners with Sandoz in Japan

emerging sectors: Report Biocon Biologics Ltd. (BBL), Based on this agreement, Viatris has has concluded an exclusive global mar-

the biosimilars subsidiary of Biocon, completed marketing and promotion of keting license agreement with BBL’s
Energy storage is becoming the next has seen unprecedented growth. Until over the past decade, ESS has gained has signed a distribution agreement the product as of December 15, 2023, affi liate. The transfer of the distribution
disruptor in the renewable energy sector 2021, only 1,794-MW of grid-scale prominence for its energy-shifting and with Sandoz, granting it the exclusive but will continue to provide transition rights of this product is part of this stra-
and the Energy Storage System (ESS) ESS capacity was awarded, excluding smoothening applications. Since solar rights to promote, sell, and distribute support until Sandoz will gradually tegy, and its addition to the product port-
market will attract the highest invest- cancelled or dormant tenders. However, and wind power supply fl uctuates, ESS ‘Adalimumab BS’ for subcutaneous assume responsibilities for the product folio will strengthen Sandoz’s immuno-
ment among emerging sectors, accord- tender issuance has shot up to about 35-GW plays a crucial role in “smoothing out” injection in Japan. Adalimumab BS starting February 15, 2024, according logy and biosimilar portfolio.
ing to a report by the Institute for Energy in just two years. intermittency and enabling a continuous for subcutaneous injection (FKB) is a to a company release.
Economics and Financial Analysis (IEE- supply of energy when needed. biosimilar of ‘Humira’ and is indicated Integration ahead of schedule.
FA) and JMK Research & Analytics. As of November 2023, a cumula- for immune-related diseases such as BBL has acquired the global biosimi- Meanwhile, BBL also recently
tive grid-scale ESS capacity of 8-GW India aims to augment its VRE ins- rheumatoid arthritis, psoriasis vulgaris, lars portfolio of Viatris, including Adali- announced that the integration of the
ESS, the missing link in India’s has been awarded, of which 5-GW was talled capacity (i.e., solar and wind) from ankylosing spondylitis, Crohn’s disease, mumab. Fujifi lm Kyowa Kirin Biologics acquired Viatris’ biosimilars business
power transformation, will be crucial awarded in 2023. Battery-based ESS 117-GW in November 2023. Higher and ulcerative colitis. Co. Ltd., the developer of the drug, in 120 countries is ahead of schedule.
in meeting the country’s non-fossil fuel (BESS) and pumped hydro storage VRE penetration has to be supported
capacity of 500-GW by 2030. Grid-scale (PHS) are prominent, commercially by a simultaneous growth in ESS capacity. LICENSING AGREEMENT
ESS promises to provide energy that is viable means for implementing energy “Renewable energy capacity additions
cheaper than traditional fossil fuel-based storage solutions now. Currently, PHS to grid infrastructure cannot sustain Intas inks deal with Spanish fi rm to sell biosimilar
generation, as costs fall over lengthy dominates the ESS market, accounting long-term without a concurrent equiv-
project tenures. for more than half of grid-scale tender alent rise in the grid-scale ESS system etanercept
capacity issued in 2023. capacity,” the report stated.
Sharp rise Intas Pharmaceuticals has entered facturing, and supply of the etanercept generic unit of Novartis, and Samsung
ESS is still an emerging sector in Globally, ESS has been used as The Central Electricity Authority’s into a licensing agreement with Span- biosimilar. Bioepis, are locked in litigation over
India. However, storage is slowly gaining ancillary support for the grid, aiding in (CEA) latest optimal generation mix ish biopharma company, mAbxience, patents. The patents of Enbrel were
prominence as a crucial component in frequency regulation and grid stability. report indicates that India will need at for marketing and distribution of the Etanercept was approved for use over already expired in the EU and many
improving power quality. In the past few However, given the rise in variable least 41.7-GW)/208.3-GWh of BESS latter’s biosimilar etanercept in more 20 years ago, offering patients a valuable other countries, allowing for the entry
years, grid-scale ESS tendering in India renewable energy (VRE) in the grid and 18.9-GW of PHS by 2029-30. than 150 countries including Europe therapeutic option for treating various of biosimilars.
POLICY DECISION and US. Financial terms of the deal autoimmune diseases. According to “Partnering up with mAbxience,
IQVIA, global sales of etanercept for the
were not disclosed.
Govt. not considering any new PLI schemes: DPIIT mAbxience, a majority-owned 12 months ending June 2023 is $11-bn. who are known for their dedication to
quality and innovation, aligns perfectly
Secretary company of German drug maker, Two of the patents in US for Enbrel, with our vision. Together, we aim to
Fresenius Kabi, which also has partial the branded version of Etanercept mar- revolutionise the landscape of autoim-
The Government will not expand nal Trade (DPIIT), of the commerce and critical key starting materials/drug inter- ownership from Insud Pharma, will be keted by Amgen, are expected to ex- mune disease treatment,” said Intas’
the scope and coverage of its produc- industry ministry. “Right now, the kitty is mediaries and active pharmaceutical responsible for the development, manu- pire only in November 2028. Sandoz, a Vice Chairman, Mr. Binish Chudgar.
tion-linked incentive (PLI) scheme dur- suffi cient, and this government feels the ingredients; manufacturing of medical
ing the ongoing fi scal year (2023-2024) allocation is suffi cient. The output of PLI devices; automobiles and auto components; Lupin’s Swiss subsidiary to buy Sanofi brands
and is likely to wait for the formation schemes this year (so far) is not as high pharmaceuticals; specialty steel; telecom
of a new Central Government next year as we expected, but the performance in and networking products; electronic/
to decide on enlarging the list of sectors terms of sales and exports has been rea- technology products; white goods; food Lupin has announced that its Swiss ‘Nalcrom’ in Canada and the Nether- brands being acquired are expected
getting incentives for building domestic sonably good,” he added without elabo- products; textile products: MMF segment subsidiary, Lupin Atlantis Holdings lands. The purchase consideration to strengthen Lupin’s respiratory seg-
manufacturing capabilities. rating on the numbers. and technical textiles; high-effi ciency SA, had signed an Asset Purchase was €10-mn (Rs. 91-crore), besides ment.
solar PV modules; advanced chemistry Agreement with French multinational sales milestones up to €8-mn (Rs.
“No new PLI scheme is being consi- The focus of the government now is cell (ACC) battery, and drones and Sanofi to acquire a portfolio of esta- 72-crore), dependant on future sales, The transaction will require appro-
dered by the government, as it feels the to strengthen and support the existing PLI drone components. As of June 2023, 733 blished products in Europe and Canada. it said. The turnover of the brands val from the Foreign Direct Investment
ongoing schemes are suffi cient,” said schemes across 14 key sectors. These 14 applications under the scheme across in these markets for the year ended Bureau of Canada, Lupin said, adding
Mr. Rajesh Kumar Singh, Secretary, Depart- sectors included mobile manufacturing 14 sectors with an expected investment The company said it was acquir- March 31, 2023 was about $6.494- that the acquisition was expected to be
ment for Promotion of Industry and Inter- and specifi ed electronic components; of Rs. 3.65 trillion were approved. ing brands ‘Aarane’ in Germany and mn (Rs. 53-crore), Lupin said. The completed by the fi rst quarter 2024.

142 Chemical Weekly January 2, 2024 Chemical Weekly January 2, 2024 143

Contents Index to Advertisers Index to Products Advertised